74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Catalyst Pharmaceuticals Inc
Open
SectorHealthcare
23.85 -2.25
Overview
Share price change
24h
Min
23.22
Max
24.55
Income | 12M 56M |
|---|---|
Sales | 13M 142M |
P/E Sector Avg | 18.799 63.778 |
EPS | 0.7 |
Profit margin | 39.442 |
Employees | 181 |
EBITDA | 21M 72M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +41.43% upside |
Next Earnings | 7 May 2025 |
|---|
Market Cap | 463M 3B |
|---|---|
Previous open | 26.1 |
Previous close | 23.85 |
News Sentiment
By Acuity
25%
75%
66 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Catalyst Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Catalyst Pharmaceuticals Inc Forecast
Price Target
By TipRanks
41.43% upside
12 Months Forecast
Average 33.83 USD 41.43%
High 40 USD
Low 31 USD
Based on 7 Wall Street analysts offering 12 month price targets forCatalyst Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
66 / 386 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
